Posted: December 21, 2024 at 2:54 am
NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Syntekabio (KOSDAQ: 226330), a leading artificial intelligence (AI)-driven drug development company, is pleased to announce its participation in Biotech Showcase 2025, taking place January 13–15, 2025, in San Francisco.
Read the original here:
Syntekabio to Showcase AI-Driven Drug Discovery Solutions at Biotech Showcase 2025
Posted: December 21, 2024 at 2:54 am
BOSTON, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for IMCIVREE® (setmelanotide) to include children as young as 2 years old. IMCIVREE is indicated to reduce excess body weight and maintain weight reduction long-term in patients 2 years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or leptin receptor (LEPR) deficiency.
Posted: December 21, 2024 at 2:54 am
TEL AVIV, Israel, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter and full year 2024 financial results, as well as on its financial guidance for 2025, on Wednesday, January 29, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.
Posted: December 21, 2024 at 2:53 am
Confirms Previously Disclosed and Anticipated FDA Decision Confirms Previously Disclosed and Anticipated FDA Decision
Read the original:
Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)
Posted: December 21, 2024 at 2:53 am
MIAMI and BARRANQUILLA, Colombia, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services company, today announced significant outcomes from its recent Shareholders Meeting and subsequent Board of Directors meeting. These include changes to the Board composition, restructuring of Board committees, and updates to its executive leadership team.
Excerpt from:
Procaps Group Announces Key Shareholder and Board Decisions, Committee Restructuring, and Leadership Updates
Posted: December 21, 2024 at 2:53 am
TORONTO, Dec. 20, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce its financial and operational results for the year ended August 31, 2024, the highlights of which are included in this news release. All figures are reported in Canadian dollars. The Company’s full set of consolidated audited financial statements for the years ended August 31, 2024 and 2023 and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at www.PharmAla.ca and its profile page on SEDAR+ at www.sedarplus.ca.
Read the original here:
PharmAla Issues Audited Financial Statements, Completes Continuance to Ontario, and Closes Private Placement
Posted: December 7, 2024 at 2:50 am
TEL AVIV, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Today, Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced that it has entered into an agreement with JKI, established by the fund managed and operated by J-Will, whereby all shares of Teva Takeda Pharma Limited and its wholly owned subsidiary Teva Takeda Yakuhin Ltd. will be transferred to JKI.
Originally posted here:
Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan
Posted: December 7, 2024 at 2:50 am
Basel, December 6, 2024 – Novartis today announced positive topline results from APPULSE-PNH, a Phase IIIB study evaluating the efficacy and safety of twice-daily oral monotherapy Fabhalta® (iptacopan) in adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who were switched from anti-C5 therapies (Hb ?10g/dL following treatment with eculizumab or ravulizumab)1. After 24 weeks of treatment with Fabhalta, the average Hb level improved versus baseline1.
Continue reading here:
New Phase IIIB data shows Novartis Fabhalta® improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from...
Posted: December 7, 2024 at 2:50 am
Availability of the revised financial statements for Sanofi excluding Opella
See the original post:
Press Release: Availability of the revised financial statements for Sanofi excluding Opella
